{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:44:22Z","timestamp":1772765062668,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.transproceed.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:32:16Z","timestamp":1724344336000},"page":"1671-1677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate\/Tacrolimus"],"prefix":"10.1016","volume":"56","author":[{"given":"Karam","family":"Ashouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anush","family":"Ginosyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carissa M.","family":"Feliciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Rodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karrune","family":"Woan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preet","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Yaghmour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.transproceed.2024.08.004_bib0001","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transproceed.2024.08.004_bib0002","article-title":"Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell","volume":"22","author":"Skiba","year":"2008","journal-title":"Oncol Nurse Ed"},{"issue":"4901","key":"10.1016\/j.transproceed.2024.08.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/200084a0","article-title":"Prolongation of homograft survival in mice with single doses of cyclophosphamide","volume":"200","author":"Berenbaum","year":"1963","journal-title":"Nature"},{"key":"10.1016\/j.transproceed.2024.08.004_bib0004","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.transproceed.2024.08.004_bib0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.transproceed.2024.08.004_bib0006","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood.V80.2.560.560","article-title":"Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia","volume":"80","author":"Storb","year":"1992","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.transproceed.2024.08.004_bib0007","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.transproceed.2024.08.004_bib0008","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.transproceed.2024.08.004_bib0009","volume":"122","author":"Kanakry","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transproceed.2024.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transproceed.2024.08.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.transproceed.2024.08.004_bib0012","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.transproceed.2024.08.004_bib0013","article-title":"Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703","volume":"140","author":"Holtan","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.transproceed.2024.08.004_bib0014","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.transproceed.2024.08.004_bib0015","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.transproceed.2024.08.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1950.1950","article-title":"Use of post-transplant cyclophosphamide (PTCy) with mycophenolate mofetil and tacrolimus in HLA matched allogeneic hematopoietic cell transplant is safe and associated with acceptable transplant outcomes","volume":"126","author":"Hess","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transproceed.2024.08.004_bib0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41409-018-0367-2","article-title":"Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10\/10 HLA-matched unrelated donor hematopoietic stem cell transplantation","volume":"54","author":"Shah","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.transproceed.2024.08.004_bib0018","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/cncr.30180","article-title":"Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation","volume":"122","author":"Gaballa","year":"2016","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.transproceed.2024.08.004_bib0019","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.transproceed.2024.08.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.transproceed.2024.08.004_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571884","article-title":"Age related differences in the biology of chronic graft-versus-host disease after hematopoietic stem cell transplantation","volume":"11","author":"Cuvelier","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.transproceed.2024.08.004_bib0022","article-title":"Immune reconstitution in the aging host: opportunities for mechanism-based therapy in allogeneic hematopoietic cell transplantation","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.transproceed.2024.08.004_bib0023","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transproceed.2024.08.004_bib0024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.56875\/2589-0646.1065","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host-disease prophylaxis compared to methotrexate-cyclosporine a in matched-related allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Shouman","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"10.1016\/j.transproceed.2024.08.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.transproceed.2024.08.004_bib0026","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2016.144253","article-title":"Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia","volume":"102","author":"Oran","year":"2017","journal-title":"Haematologica"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524004329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524004329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T05:48:30Z","timestamp":1734155310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134524004329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0041134524004329"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2024.08.004","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate\/Tacrolimus","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}